Early neurological deterioration following intravenous recombinant tissue plasminogen activator therapy in patients with acute lacunar stroke

Cerebrovascular Diseases

Volumn 26, Issue 4, 2008, Pages 355-359

  Hwang, Yang Ha ^a   Seo, Jong Geun ^a   Lee, Ho Won ^a   Park, Sung Pa ^a   Suh, Chung Kyu ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Acute stroke syndromes; Lacunar infarction; Recombinant tissue plasminogen activator; Thrombolysis

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT;

ACUTE LACUNAR STROKE; ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; NEUROLOGIC DETERIORATION; NEUROLOGIC DISEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; BRAIN INFARCTION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 50049098871     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151638     Document Type: Article

References (20)

1. Kwan J, Hand P: Early neurological deterioration in acute stroke: clinical characteristics and impact on outcome. QJM 2006;99:625-633.
2. Steinke W, Ley SC: Lacunar stroke is the major cause of progressive motor deficits. Stroke 2002;33:1510-1516.
3. Norrving B: Long-term prognosis after lacunar infarction. Lancet Neurol 2003;2:238-245.
4. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC: Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology 2003;61:71-75.
5. Grotta J: Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? t-PA - the best current option for most patients. N Engl J Med 1997;337:1310-1313.
6. Cocho D, Belvis R, Marti-Fabregas J, Bravo Y, Aleu A, Pagonabarraga J, Molina-Porcel L, Diaz-Manera J, San Roman L, Martinez-Lage M, Martinez A, Moreno M, Marti-Vilalta JL: Does thrombolysis benefit patients with lacunar syndrome? Eur Neurol 2006;55:70-73.
7. Caplan LR, Mohr JP, Kistler JP, Koroshetz W: Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis - not a panacea for ischemic stroke. N Engl J Med 1997;337:1309-1310; discussion 1313.
8. Kaur J, Zhao Z, Klein GM, Lo EH, Buchan AM: The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004;24:945-963.
9. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35:2726-2730.
10. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-1526.
11. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 1993;24:35-41.
12. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
13. Adams HP Jr, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W: Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis 2004;18:124-129.
14. Nakamura K, Saku Y, Ibayashi S, Fujishima M: Progressive motor deficits in lacunar infarction. Neurology 1999;52:29-33.
15. Kim YS, Lee KY, Koh SH, Park CY, Kim HY, Lee YJ, Kim HT, Kim J, Kim MH, Kim KS, Chang DI, Kim SH: The role of matrix metalloproteinase 9 in early neurological worsening of acute lacunar infarction. Eur Neurol 2006;55:11-15.
16. Castillo J: Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment. Cerebrovasc Dis 1999;9(suppl 3):1-8.
17. Audebert HJ, Pellkofer TS, Wimmer ML, Haberl RL: Progression in lacunar stroke is related to elevated acute phase parameters. Eur Neurol 2004;51:125-131.
18. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, Christianson TJ: Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004;35:2418-2424.
19. Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A: Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002;33:982-987.
20. Toni D, Iweins F, von Kummer R, Busse O, Bogousslavsky J, Falcou A, Lesaffre E, Lenzi GL: Identification of lacunar infarcts before thrombolysis in the ECASS I study. Neurology 2000;54:684-688.